Chris Howerton
Stock Analyst at Jefferies
(2.57)
# 2,284
Out of 4,959 analysts
73
Total ratings
44.83%
Success rate
15.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Howerton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Maintains: Buy | $11 → $8 | $6.11 | +30.93% | 5 | Jan 2, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $79 | $19.38 | +307.64% | 2 | Sep 29, 2023 | |
| MIST Milestone Pharmaceuticals | Downgrades: Hold | $8 → $4 | $1.71 | +133.92% | 4 | Jun 20, 2023 | |
| VERU Veru Inc. | Upgrades: Hold | $10 | $3.55 | +181.69% | 3 | Jun 7, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | $320 → $352 | $5.23 | +6,630.40% | 2 | Mar 10, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Underperform | $720 | $9.42 | +7,543.31% | 2 | Feb 8, 2023 | |
| CGEN Compugen | Downgrades: Underperform | $0.5 | $1.43 | -65.03% | 2 | Feb 8, 2023 | |
| URGN UroGen Pharma | Downgrades: Hold | $35 → $10 | $19.78 | -49.44% | 1 | Feb 8, 2023 | |
| MEIP MEI Pharma | Downgrades: Underperform | $8 → $2 | $4.62 | -56.71% | 3 | Feb 8, 2023 | |
| AVDL Avadel Pharmaceuticals | Upgrades: Buy | $6.5 → $11 | $14.82 | -25.78% | 3 | Nov 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $70 → $40 | $27.62 | +44.82% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $57 → $61 | $37.29 | +63.58% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $117.14 | -23.17% | 3 | Sep 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $24 → $12 | $4.51 | +166.08% | 11 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $1.77 | +1,029.94% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $22.02 | +199.73% | 9 | Sep 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $5.79 | +279.97% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $1.74 | +1,106.90% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $1.28 | +1,618.75% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.55 | +1,383.87% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $21 | $24.79 | -15.27% | 6 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $80 → $580 | $18.32 | +3,065.94% | 2 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $63 → $60 | $1.08 | +5,455.56% | 1 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 | $71.03 | -77.47% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $56.04 | -51.82% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,200 | $7.34 | +16,248.77% | 1 | May 26, 2020 |
Ardelyx
Jan 2, 2025
Maintains: Buy
Price Target: $11 → $8
Current: $6.11
Upside: +30.93%
Structure Therapeutics
Sep 29, 2023
Maintains: Buy
Price Target: $50 → $79
Current: $19.38
Upside: +307.64%
Milestone Pharmaceuticals
Jun 20, 2023
Downgrades: Hold
Price Target: $8 → $4
Current: $1.71
Upside: +133.92%
Veru Inc.
Jun 7, 2023
Upgrades: Hold
Price Target: $10
Current: $3.55
Upside: +181.69%
BioXcel Therapeutics
Mar 10, 2023
Downgrades: Hold
Price Target: $320 → $352
Current: $5.23
Upside: +6,630.40%
Avalo Therapeutics
Feb 8, 2023
Downgrades: Underperform
Price Target: $720
Current: $9.42
Upside: +7,543.31%
Compugen
Feb 8, 2023
Downgrades: Underperform
Price Target: $0.5
Current: $1.43
Upside: -65.03%
UroGen Pharma
Feb 8, 2023
Downgrades: Hold
Price Target: $35 → $10
Current: $19.78
Upside: -49.44%
MEI Pharma
Feb 8, 2023
Downgrades: Underperform
Price Target: $8 → $2
Current: $4.62
Upside: -56.71%
Avadel Pharmaceuticals
Nov 30, 2022
Upgrades: Buy
Price Target: $6.5 → $11
Current: $14.82
Upside: -25.78%
Nov 10, 2022
Downgrades: Hold
Price Target: $70 → $40
Current: $27.62
Upside: +44.82%
Oct 14, 2022
Upgrades: Buy
Price Target: $57 → $61
Current: $37.29
Upside: +63.58%
Sep 30, 2022
Maintains: Buy
Price Target: $92 → $90
Current: $117.14
Upside: -23.17%
Feb 25, 2022
Downgrades: Hold
Price Target: $24 → $12
Current: $4.51
Upside: +166.08%
Nov 30, 2021
Initiates: Buy
Price Target: $20
Current: $1.77
Upside: +1,029.94%
Sep 17, 2021
Initiates: Buy
Price Target: $66
Current: $22.02
Upside: +199.73%
Aug 23, 2021
Initiates: Buy
Price Target: $22
Current: $5.79
Upside: +279.97%
Aug 10, 2021
Initiates: Buy
Price Target: $21
Current: $1.74
Upside: +1,106.90%
May 25, 2021
Initiates: Buy
Price Target: $22
Current: $1.28
Upside: +1,618.75%
Apr 19, 2021
Initiates: Buy
Price Target: $23
Current: $1.55
Upside: +1,383.87%
Apr 6, 2021
Downgrades: Hold
Price Target: $40 → $21
Current: $24.79
Upside: -15.27%
Aug 11, 2020
Upgrades: Buy
Price Target: $80 → $580
Current: $18.32
Upside: +3,065.94%
Aug 7, 2020
Downgrades: Underperform
Price Target: $63 → $60
Current: $1.08
Upside: +5,455.56%
Aug 5, 2020
Downgrades: Hold
Price Target: $16
Current: $71.03
Upside: -77.47%
Jul 15, 2020
Initiates: Buy
Price Target: $27
Current: $56.04
Upside: -51.82%
May 26, 2020
Initiates: Buy
Price Target: $1,200
Current: $7.34
Upside: +16,248.77%